Epicardial and microvascular graft vessel disease in children

N E Hiemann1, E Wellnhofer, H Abdul-Khaliq

  • 1Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany. hiemann@dhzb.de

Insights

Graft vessel disease (GVD) significantly impacts long-term survival in pediatric heart transplant recipients. Both microvascular and macrovascular GVD are common complications in these young patients.

Area of Science:

  • Cardiology
  • Transplantation Immunology
  • Pediatric Medicine

Background:

  • Graft vessel disease (GVD) is a major challenge affecting long-term outcomes in heart transplantation (HTx).
  • The prevalence and characteristics of GVD in pediatric recipients require further investigation.

Purpose of the Study:

  • To determine the incidence of epicardial and microvascular GVD in pediatric patients following heart and heart-lung transplantation.
  • To assess the relationship between rejection, vascular changes, and GVD in this population.

Main Methods:

  • Analysis of 137 coronary angiographies from 130 pediatric HTx and heart and lung transplant (HLTx) patients (aged 0-18 years).
  • Evaluation of angiographic findings using the Stanford classification and assessment of minor vessel alterations.
  • Microscopic examination of 397 endomyocardial biopsies (EMBs) for acute cellular rejection and vascular reactions.

Main Results:

  • Moderate and severe acute cellular rejection were observed in 32.8% and 13.3% of EMBs, respectively.
  • Microvascular changes, including endothelial cell swelling (33.5%) and vessel wall thickening (53.8%), were prevalent.
  • Coronary angiography revealed significant macrovascular alterations: Stanford lesions (61.2%), peripheral obliterations (52.5%), diameter fluctuations (86.3%), and pathologic tapering (64.0%).
  • Long-term survivors (≥5 years) exhibited high rates of both macrovascular (78%) and microvascular (67%) alterations.

Conclusions:

  • Microvascular and macrovascular GVD are predominant complications in pediatric HTx and HLTx long-term survivors.
  • These findings underscore the clinical significance of GVD in pediatric transplant recipients and the need for monitoring.
Abstract